Commitments and Contingencies |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Commitments and Contingencies Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Commitments and Contingencies | Note 8 – Commitments and Contingencies
Legal Matters
In the ordinary course of business, we are from time to time involved in lawsuits, claims, investigations, proceedings, and threats of litigation relating to, among other things, intellectual property, commercial arrangements, employment, and regulatory matters. No governmental proceedings are pending or, to our knowledge, contemplated against us.
The Company is one of many companies and underwriters named as defendants in three class action lawsuits filed in 2026 in New York State court. The lawsuits claim that shares of several small companies, including the Company, were promoted on social media to inflate their prices, and that the offering documents for those companies’ initial public offerings, including the Company’s December 2024 IPO, did not disclose this risk. The plaintiffs are seeking unspecified damages. No directors or officers of the Company are named.
In October 2026, the plaintiffs in two of the lawsuits asked the court to drop their claims against the Company. The court has not yet approved these requests. The third lawsuit remains pending.
The lawsuits are at an early stage, and the Company cannot estimate any possible loss. No liability has been recorded as of September 30, 2026. The Company has notified its insurance carrier of the lawsuits.
Office Lease
On May 1, 2021, the Company entered into a 61-month operating lease for office space for a base rent of $3,783 subject to a 3% yearly escalation. The lease terminated on May 31, 2026.
On June 1, 2026, the Company commenced a new operating lease for office space with a term of 76 months. This lease provides for an initial monthly base rent of $3,650 subject to a 3% yearly escalation.
As of September 30, 2026, the Company’s operating lease right-of-use asset, net (ROU) is $211,070 and the total lease liability is $225,049 based on an incremental borrowing rate of 8%.
Future minimum lease liability payments under the non-cancellable operating lease at September 30, 2026 is as follows:
Consulting Agreements
On December 15, 2024, the Company entered into a 36-month strategic services agreement with Dominant Treasure Health Company Limited to support product development and distribution in Southeast Asia for a $2.3 million fee, plus a 5% success fee on certain distribution-related payments. The $2.3 million fee is being expensed over the agreement term. For the nine months ended September 30, 2026 and 2025, the Company recognized $573,425 and $573,424, respectively, of related consulting expense.
Licensing and Royalty Agreements - Aquanova AG
On September 13, 2016, the Company entered into a license agreement with Aquanova AG granting the Company exclusive worldwide rights to develop, manufacture and commercialize JOTROL™ and related products. The agreement provides for annual license fees of $75,000 until marketing approval, milestone payments of $200,000 per approved territory, up to $600,000, and royalties of 5% of net sales, subject to an option to reduce the royalty to 1.25% in exchange for a $3.0 million payment following U.S. marketing approval. No marketing approval had been received as of September 30, 2026.
As of September 30, 2026 and December 31, 2025, $56,250 and $0 of accrued license fees are included in accounts payable and accrued expenses on the balance sheet, respectively.
Licensing and Royalty Agreements – PharmAla Biotech Holdings Inc.
Pursuant to the Strategic Asset License Agreement with PharmAla, the Company is obligated to make development milestone payments totaling up to $23,333,333, consisting of (i) $3,333,333 upon first dosing of the first patient in a Phase 3 clinical trial, payable 50% in cash and 50%, at PharmAla’s election, in cash or common stock, and (ii) $20,000,000 upon first FDA approval of a New Drug Application for a licensed product, payable in cash.
The Company is also obligated to make commercialization milestone payments totaling up to $73,333,333, consisting of (i) $10,000,000 upon achieving $333,333,333 in net sales, (ii) $30,000,000 upon achieving $1,000,000,000 in net sales, and (iii) $33,333,333 upon achieving $2,000,000,000 in net sales. Each milestone payment is payable only once upon achievement of the applicable milestone.
Beginning with the calendar quarter in which the third commercialization milestone becomes payable, the Company is required to pay PharmAla a royalty of 3% of net sales of licensed products in the territory for the remaining term of the agreement.
See Note 6 – PharmAla License Agreement and Share-Settlement Liability for additional information.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||